Literature DB >> 26215113

von Willebrand factor propeptide: biology and clinical utility.

Sandra L Haberichter1.   

Abstract

von Willebrand factor (VWF) is a large multimeric glycoprotein that mediates the attachment of platelets to damaged endothelium and also serves as the carrier protein for coagulation factor VIII (FVIII), protecting it from proteolytic degradation. Quantitative or qualitative defects in VWF result in von Willebrand disease (VWD), a common inherited bleeding disorder. VWF is synthesized with a very large propeptide (VWFpp) that is critical for intracellular processing of VWF. VWFpp actively participates in the process of VWF multimerization and is essential for trafficking of VWF to the regulated storage pathway. Mutations identified within VWFpp in VWD patients are associated with altered VWF structure and function. The assay of plasma VWFpp has clinical utility in assessing acute and chronic vascular perturbation associated with diseases such as thrombotic thrombocytopenic purpura, sepsis, and diabetes among others. VWFpp assay also has clear utility in the diagnosis of VWD subtypes, particularly in discriminating true type 3 subjects from type 1C (reduced plasma survival of VWF), which is clinically important and has implications for therapeutic treatment.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26215113      PMCID: PMC4600015          DOI: 10.1182/blood-2015-04-512731

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  99 in total

1.  von Willebrand factor storage and multimerization: 2 independent intracellular processes.

Authors:  S L Haberichter; S A Fahs; R R Montgomery
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

2.  Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice.

Authors:  C V Denis; P André; S Saffaripour; D D Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

3.  Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.

Authors:  X Zheng; D Chung; T K Takayama; E M Majerus; J E Sadler; K Fujikawa
Journal:  J Biol Chem       Date:  2001-09-13       Impact factor: 5.157

Review 4.  Von Willebrand factor propeptide in vascular disorders.

Authors:  J A van Mourik; T Romani de Wit
Journal:  Thromb Haemost       Date:  2001-07       Impact factor: 5.249

5.  Two Cys residues essential for von Willebrand factor multimer assembly in the Golgi.

Authors:  Angie R Purvis; Julia Gross; Luke T Dang; Ren-Huai Huang; Milan Kapadia; R Reid Townsend; J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-25       Impact factor: 11.205

6.  Thrombocytopenia and release of activated von Willebrand Factor during early Plasmodium falciparum malaria.

Authors:  Quirijn de Mast; Evelyn Groot; Peter J Lenting; Philip G de Groot; Matthew McCall; Robert W Sauerwein; Rob Fijnheer; Andre van der Ven
Journal:  J Infect Dis       Date:  2007-07-10       Impact factor: 5.226

7.  Assembly of Weibel-Palade body-like tubules from N-terminal domains of von Willebrand factor.

Authors:  Ren-Huai Huang; Ying Wang; Robyn Roth; Xiong Yu; Angie R Purvis; John E Heuser; Edward H Egelman; J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-08       Impact factor: 11.205

8.  Reduced von Willebrand factor survival in type Vicenza von Willebrand disease.

Authors:  Alessandra Casonato; Elena Pontara; Francesca Sartorello; Maria Grazia Cattini; Maria Teresa Sartori; Roberto Padrini; Antonio Girolami
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

9.  Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma).

Authors:  A Scheja; A Akesson; P Geborek; M Wildt; C B Wollheim; F A Wollheim; U M Vischer
Journal:  Arthritis Res       Date:  2001-02-19

10.  Rate, extent and concentration dependence of histamine-evoked Weibel-Palade body exocytosis determined from individual fusion events in human endothelial cells.

Authors:  M Erent; A Meli; N Moisoi; V Babich; M J Hannah; P Skehel; L Knipe; G Zupancic; D Ogden; T Carter
Journal:  J Physiol       Date:  2007-05-31       Impact factor: 5.182

View more
  16 in total

1.  Genome-wide studies of von Willebrand factor propeptide identify loci contributing to variation in propeptide levels and von Willebrand factor clearance.

Authors:  A B Ozel; B McGee; D Siemieniak; P M Jacobi; S L Haberichter; L C Brody; J L Mills; A M Molloy; D Ginsburg; J Z Li; K C Desch
Journal:  J Thromb Haemost       Date:  2016-08-19       Impact factor: 5.824

2.  von Willebrand factor propeptide to antigen ratio identifies platelet activation and reduced von Willebrand factor survival phenotype in mice.

Authors:  P M Jacobi; S Kanaji; D Jakab; A L Gehrand; J M Johnsen; S L Haberichter
Journal:  J Thromb Haemost       Date:  2018-01-24       Impact factor: 5.824

3.  Robust prognostic model based on immune infiltration-related genes and clinical information in ovarian cancer.

Authors:  Xi Zhang; Weikaixin Kong; Miaomiao Gao; Weiran Huang; Chao Peng; Zhuo Huang; Zhengwei Xie; Hongyan Guo
Journal:  J Cell Mol Med       Date:  2022-06-23       Impact factor: 5.295

Review 4.  New developments in von Willebrand disease.

Authors:  Helen Fogarty; Dearbhla Doherty; James S O'Donnell
Journal:  Br J Haematol       Date:  2020-05-12       Impact factor: 6.998

5.  Whole-exome sequencing identifies rare variants in STAB2 associated with venous thromboembolic disease.

Authors:  Karl C Desch; Ayse B Ozel; Matt Halvorsen; Paula M Jacobi; Krista Golden; Mary Underwood; Marine Germain; David-Alexandre Tregouet; Pieter H Reitsma; Clive Kearon; Lauren Mokry; J Brent Richards; Frances Williams; Jun Z Li; David Goldstein; David Ginsburg
Journal:  Blood       Date:  2020-07-30       Impact factor: 25.476

Review 6.  Diagnosis and Treatment of von Willebrand Disease and Rare Bleeding Disorders.

Authors:  Giancarlo Castaman; Silvia Linari
Journal:  J Clin Med       Date:  2017-04-10       Impact factor: 4.241

7.  von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C.

Authors:  Hiroaki Takaya; Hideto Kawaratani; Yuki Tsuji; Keisuke Nakanishi; Soichiro Saikawa; Shinya Sato; Yasuhiko Sawada; Kosuke Kaji; Yasushi Okura; Naotaka Shimozato; Mitsuteru Kitade; Takemi Akahane; Kei Moriya; Tadashi Namisaki; Akira Mitoro; Masanori Matsumoto; Hiroshi Fukui; Hitoshi Yoshiji
Journal:  United European Gastroenterol J       Date:  2018-05-25       Impact factor: 4.623

Review 8.  The relationship between ABO blood group, von Willebrand factor, and primary hemostasis.

Authors:  Soracha E Ward; Jamie M O'Sullivan; James S O'Donnell
Journal:  Blood       Date:  2020-12-17       Impact factor: 22.113

Review 9.  Regulation of plasma von Willebrand factor.

Authors:  Karl C Desch
Journal:  F1000Res       Date:  2018-01-23

10.  Large-scale Multi-omic Analysis of COVID-19 Severity.

Authors:  Katherine A Overmyer; Evgenia Shishkova; Ian J Miller; Joseph Balnis; Matthew N Bernstein; Trenton M Peters-Clarke; Jesse G Meyer; Qiuwen Quan; Laura K Muehlbauer; Edna A Trujillo; Yuchen He; Amit Chopra; Hau C Chieng; Anupama Tiwari; Marc A Judson; Brett Paulson; Dain R Brademan; Yunyun Zhu; Lia R Serrano; Vanessa Linke; Lisa A Drake; Alejandro P Adam; Bradford S Schwartz; Harold A Singer; Scott Swanson; Deane F Mosher; Ron Stewart; Joshua J Coon; Ariel Jaitovich
Journal:  medRxiv       Date:  2020-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.